Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical caspofungin versus topical voriconazole for fungal keratitis
IRCT20231219060471N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of caspofungin and voriconazole in keratomycosis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Treatment of fungal corneal ulcer, Visual acuity improvement and 4 more. Started Jan 2024; status: completed.
02
Drugs
caspofunginvoriconazole
03
Conditions
keratomycosis
Beyond the preview
Go deeper on IRCT20231219060471N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231219060471N1.